{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:52:30Z","timestamp":1773168750679,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PRO Consortium"},{"name":"eCOA Consortium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-02165-1","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:01:51Z","timestamp":1765792911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Best practice recommendations and considerations for designing and electronically implementing event-driven diaries in clinical trials"],"prefix":"10.1038","volume":"8","author":[{"given":"Florence D.","family":"Mowlem","sequence":"first","affiliation":[]},{"given":"Jeremiah J.","family":"Trudeau","sequence":"additional","affiliation":[]},{"given":"Jill V.","family":"Platko","sequence":"additional","affiliation":[]},{"given":"Jos","family":"Bloemers","sequence":"additional","affiliation":[]},{"given":"Emuella","family":"Flood","sequence":"additional","affiliation":[]},{"given":"Jessica L.","family":"Abel","sequence":"additional","affiliation":[]},{"given":"Kelly","family":"Dumais","sequence":"additional","affiliation":[]},{"given":"Paul","family":"O\u2019Donohoe","sequence":"additional","affiliation":[]},{"given":"Sabrina","family":"Grant","sequence":"additional","affiliation":[]},{"given":"Ryan","family":"Naville-Cook","sequence":"additional","affiliation":[]},{"given":"Onyekachukwu","family":"Illoh","sequence":"additional","affiliation":[]},{"given":"Shannon D.","family":"Keith","sequence":"additional","affiliation":[]},{"given":"Jing","family":"Ju","sequence":"additional","affiliation":[]},{"given":"Megan","family":"Fitter","sequence":"additional","affiliation":[]},{"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[]},{"given":"Randall","family":"Winnette","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Bossi","sequence":"additional","affiliation":[]},{"given":"Naomi","family":"Suminski","sequence":"additional","affiliation":[]},{"given":"Sonya","family":"Eremenco","sequence":"additional","affiliation":[]},{"given":"Lindsay","family":"Hughes","sequence":"additional","affiliation":[]},{"given":"Amy","family":"Fasiczka","sequence":"additional","affiliation":[]},{"given":"Luisana","family":"Rojas","sequence":"additional","affiliation":[]},{"given":"Michelle","family":"Campbell","sequence":"additional","affiliation":[]},{"given":"Scottie","family":"Kern","sequence":"additional","affiliation":[]},{"name":"On Behalf of the Electronic Clinical Outcome Assessment Consortium","sequence":"additional","affiliation":[]},{"name":"The Patient-Reported Outcome Consortium","sequence":"additional","affiliation":[]},{"given":"Jeremiah J.","family":"Trudeau","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2165_CR1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. (FDA, 2025)."},{"key":"2165_CR2","doi-asserted-by":"publisher","unstructured":"Izmailova, E. S. & Ellis, R. D. When work hits home: the cancer-treatment journey of a clinical scientist driving digital medicine. JCO Clin. Cancer Inform. https:\/\/doi.org\/10.1200\/CCI.22.00033 (2022)","DOI":"10.1200\/CCI.22.00033"},{"key":"2165_CR3","doi-asserted-by":"crossref","unstructured":"Brinkmann, B. H. et al. Seizure diaries and forecasting with wearables: epilepsy monitoring outside the clinic. Front. Neurol. 12, 690404 (2021).","DOI":"10.3389\/fneur.2021.690404"},{"key":"2165_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eplepsyres.2019.02.007","volume":"153","author":"G Regalia","year":"2019","unstructured":"Regalia, G., Onorati, F., Lai, M., Caborni, C. & Picard, R. W. Multimodal wrist-worn devices for seizure detection and advancing research: focus on the Empatica wristbands. Epilepsy Res. 153, 79\u201382 (2019).","journal-title":"Epilepsy Res."},{"key":"2165_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.yebeh.2012.04.128","volume":"24","author":"RS Fisher","year":"2012","unstructured":"Fisher, R. S. et al. Seizure diaries for clinical research and practice: limitations and future prospects. Epilepsy Behav. 24, 304\u2013310 (2012).","journal-title":"Epilepsy Behav."},{"key":"2165_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/nau.22800","volume":"35","author":"P Abrams","year":"2016","unstructured":"Abrams, P. et al. Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder. Neurourol. Urodyn. 35, 743\u2013749 (2016).","journal-title":"Neurourol. Urodyn."},{"key":"2165_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1046\/j.1464-410X.2003.04168.x","volume":"91","author":"P Quinn","year":"2003","unstructured":"Quinn, P., Goka, J. & Richardson, H. Assessment of an electronic daily diary in patients with overactive bladder. BJU Int 91, 647\u2013652 (2003).","journal-title":"BJU Int"},{"key":"2165_CR8","doi-asserted-by":"publisher","first-page":"107925","DOI":"10.1016\/j.yebeh.2021.107925","volume":"118","author":"J Patel","year":"2021","unstructured":"Patel, J. et al. Use of an electronic seizure diary in a randomized, controlled trial of natalizumab in adult participants with drug-resistant focal epilepsy. Epilepsy Behav. 118, 107925 (2021).","journal-title":"Epilepsy Behav."},{"key":"2165_CR9","doi-asserted-by":"publisher","first-page":"107379","DOI":"10.1016\/j.eplepsyres.2024.107379","volume":"203","author":"KR Miller","year":"2024","unstructured":"Miller, K. R., Barnard, S., Juarez-Colunga, E., French, J. A. & Pellinen, J. Long-term seizure diary tracking habits in clinical studies: evidence from the Human Epilepsy Project. Epilepsy Res 203, 107379 (2024).","journal-title":"Epilepsy Res"},{"key":"2165_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1177\/2168479015609649","volume":"49","author":"A Gater","year":"2015","unstructured":"Gater, A., Coon, C. D., Nelsen, L. M. & Girman, C. Unique challenges in development, psychometric evaluation, and interpretation of daily and event diaries as endpoints in clinical trials. Ther. Innov. Regul. Sci. 49, 813\u2013821 (2015).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2165_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s11136-011-0003-8","volume":"21","author":"JM Norquist","year":"2012","unstructured":"Norquist, J. M., Girman, C., Fehnel, S., DeMuro-Mercon, C. & Santanello, N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual. Life Res. 21, 1013\u20131020 (2012).","journal-title":"Qual. Life Res."},{"key":"2165_CR12","doi-asserted-by":"publisher","first-page":"S-818","DOI":"10.1016\/S0016-5085(20)32724-4","volume":"158","author":"ES Dellon","year":"2020","unstructured":"Dellon, E. S. et al. Mo1184 An Episode-based patient-reported outcome measures of dysphagia experience is feasible and not burdensome for patient with eosinophilic esophagitis. Gastroenterology 158, S-818 (2020).","journal-title":"Gastroenterology"},{"key":"2165_CR13","doi-asserted-by":"crossref","unstructured":"Khurana, L. & Emerson, J. The impact of trial design on diary compliance in clinical trials for acute and preventive migraine treatments (P7-12.001). Neurology 102, 6532 (2024).","DOI":"10.1212\/WNL.0000000000206532"},{"key":"2165_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2015.09.006","volume":"32","author":"J Bidwell","year":"2015","unstructured":"Bidwell, J., Khuwatsamrit, T., Askew, B., Ehrenberg, J. A. & Helmers, S. Seizure reporting technologies for epilepsy treatment: a review of clinical information needs and supporting technologies. Seizure 32, 109\u2013117 (2015).","journal-title":"Seizure"},{"key":"2165_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jval.2016.11.001","volume":"20","author":"SE Fehnel","year":"2017","unstructured":"Fehnel, S. E. et al. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health 20, 618\u2013626 (2017).","journal-title":"Value Health"},{"key":"2165_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-2600(24)00222-4","volume":"12","author":"SS Birring","year":"2024","unstructured":"Birring, S. S. et al. Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial. Lancet Respir. Med. 12, 855\u2013864 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2165_CR17","unstructured":"US Food and Drug Administration. Center For Drug Evaluation And Research https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212102Orig1s000OtherR.pdf (FDA, 2020). application number: 212102Orig1s000."},{"key":"2165_CR18","unstructured":"Center for Drug Evaluation and Research. Center for Drug Evaluation and Research. Application Number: 202611Orig1s000 Summary Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202611Orig1s000SumR.pdf (FDA, 2012)."},{"key":"2165_CR19","unstructured":"U. S. Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. (FDA, 2023)."},{"key":"2165_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1185\/03007990902774765","volume":"25","author":"DE Stull","year":"2009","unstructured":"Stull, D. E., Leidy, N. K., Parasuraman, B. & Chassany, O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr. Med. Res. Opin. 25, 929\u2013942 (2009).","journal-title":"Curr. Med. Res. Opin."},{"key":"2165_CR21","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1177\/0333102420949180","volume":"40","author":"VE Miller","year":"2020","unstructured":"Miller, V. E. et al. Comparing prospective headache diary and retrospective four-week headache questionnaire over 20 weeks: Secondary data analysis from a randomized controlled trial. Cephalalgia 40, 1523\u20131531 (2020).","journal-title":"Cephalalgia"},{"key":"2165_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.nurpra.2021.01.014","volume":"17","author":"M Bensink","year":"2021","unstructured":"Bensink, M. et al. Tracking migraine digitally: the future of migraine management. J. Nurse Practitioners 17, 462\u2013470 (2021).","journal-title":"J. Nurse Practitioners"},{"key":"2165_CR23","unstructured":"US Food and Drug Administration. Migraine: Developing Drugs for Acute Treatment Guidance for Industry. (FDA, 2018)."},{"key":"2165_CR24","unstructured":"Morris, C., Gibbons, E. & Fitzpatrick, R. Child and Parent Reported Outcome Measures: A Scoping Report Focusing on Feasibility for Routine Use in the NHS. (NHS, 2009)."},{"key":"2165_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","volume":"16","author":"LS Matza","year":"2013","unstructured":"Matza, L. S. et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health 16, 461\u2013479 (2013).","journal-title":"Value Health"},{"key":"2165_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s43441-022-00412-1","volume":"56","author":"FD Mowlem","year":"2022","unstructured":"Mowlem, F. D., Tenaerts, P., Gwaltney, C. & Oakley-Girvan, I. Regulatory acceptance of patient-reported outcome (PRO) data from bring-your-own-device (BYOD) solutions to support medical product labeling claims. Ther. Innov. Regul. Sci. 56, 531\u2013535 (2022).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2165_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/2168479018793369","volume":"53","author":"B Byrom","year":"2019","unstructured":"Byrom, B., Gwaltney, C., Slagle, A., Gnanasakthy, A. & Muehlhausen, W. Measurement equivalence of patient-reported outcome measures migrated to electronic formats: a review of evidence and recommendations for clinical trials and bring your own device. Ther. Innov. Regul. Sci. 53, 426\u2013430 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2165_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jval.2023.10.007","volume":"27","author":"FD Mowlem","year":"2024","unstructured":"Mowlem, F. D. et al. Best practices for the electronic implementation and migration of patient-reported outcome measures. Value Health 27, 79\u201394 (2024).","journal-title":"Value Health"},{"key":"2165_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40271-022-00611-w","volume":"16","author":"T Peasgood","year":"2023","unstructured":"Peasgood, T., Caruana, J. M. & Mukuria, C. Systematic review of the effect of a one-day versus seven-day recall duration on patient reported outcome measures (PROMs). Patient Patient-Centered Outcomes Res. 16, 201\u2013221 (2023).","journal-title":"Patient Patient-Centered Outcomes Res."},{"key":"2165_CR30","doi-asserted-by":"crossref","unstructured":"Delong, P. S. et al. Best practice recommendations for electronic clinical outcome assessment data changes. J. Soc. Clin. Data Manage. 1, 249 (2023).","DOI":"10.47912\/jscdm.249"},{"key":"2165_CR31","unstructured":"European Medicines Agency. Guideline on Computerised Systems and Electronic Data in Clinical Trials. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/draft-guideline-computerised-systems-electronic-data-clinical-trials_en.pdf (EMA, 2021)."},{"key":"2165_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev.psych.54.101601.145030","volume":"54","author":"N Bolger","year":"2003","unstructured":"Bolger, N., Davis, A. & Rafaeli, E. Diary methods: capturing life as it is lived. Annu. Rev. Psychol. 54, 579\u2013616 (2003).","journal-title":"Annu. Rev. Psychol."},{"key":"2165_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/2168479018796206","volume":"53","author":"JJ Ly","year":"2019","unstructured":"Ly, J. J. et al. Training on the use of technology to collect patient-reported outcome data electronically in clinical trials: best practice recommendations from the ePRO consortium. Ther. Innov. Regul. Sci. 53, 431\u2013440 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2165_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","volume":"12","author":"SJ Coons","year":"2009","unstructured":"Coons, S. J. et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force report. Value Health 12, 419\u2013429 (2009).","journal-title":"Value Health"},{"key":"2165_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jval.2017.07.002","volume":"21","author":"W Muehlhausen","year":"2018","unstructured":"Muehlhausen, W. et al. Standards for instrument migration when implementing paper patient-reported outcome instruments electronically: recommendations from a qualitative synthesis of cognitive interview and usability studies. Value Health 21, 41\u201348 (2018).","journal-title":"Value Health"},{"key":"2165_CR36","doi-asserted-by":"crossref","unstructured":"O\u2019Donohoe, P. et al. Updated recommendations on evidence needed to support measurement comparability among modes of data collection for patient-reported outcome measures: a good practices report of an ISPOR task force. Value Health 26, 623\u2013633 (2023).","DOI":"10.1016\/j.jval.2023.01.001"},{"key":"2165_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11136-019-02329-z","volume":"29","author":"OL Aiyegbusi","year":"2020","unstructured":"Aiyegbusi, O. L. Key methodological considerations for usability testing of electronic patient-reported outcome (ePRO) systems. Qual. Life Res. 29, 325\u2013333 (2020).","journal-title":"Qual. Life Res."},{"key":"2165_CR38","unstructured":"US Food and Drug Administration. Applying Human Factors Testing and Usability Engineering to Medical Devices. https:\/\/www.fda.gov\/media\/80481\/download (FDA, 2016)."},{"key":"2165_CR39","unstructured":"McKenzie, S. et al. Proving the eDiary dividend: eDiary data can reduce recall bias and enhance the sensitivity of PRO data, paying off in reduced error variance and significant financial savings in future clinical trials. Appl. Clin. Trials 13, https:\/\/www.appliedclinicaltrialsonline.com\/view\/proving-ediary-dividend (2004)."},{"key":"2165_CR40","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1007\/s11136-022-03198-9","volume":"31","author":"P Griffiths","year":"2022","unstructured":"Griffiths, P., Williams, A. & Brohan, E. How do the number of missing daily diary days impact the psychometric properties and meaningful change thresholds arising from a weekly average summary score? Qual. Life Res. 31, 3433\u20133445 (2022).","journal-title":"Qual. Life Res."},{"key":"2165_CR41","doi-asserted-by":"crossref","unstructured":"Delobelle, J. et al. Fitbit\u2019s accuracy to measure short bouts of stepping and sedentary behaviour: validation, sensitivity and specificity study. Digit. Health 10, 20552076241262710 (2024).","DOI":"10.1177\/20552076241262710"},{"key":"2165_CR42","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1089\/jpm.2022.0535","volume":"26","author":"T Schuler","year":"2023","unstructured":"Schuler, T. et al. Wearable-triggered ecological momentary assessments are feasible in people with advanced cancer and their family caregivers: feasibility study from an outpatient palliative care clinic at a cancer center. J. Palliat. Med. 26, 980\u2013985 (2023).","journal-title":"J. Palliat. Med."},{"key":"2165_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/dia.2014.0407","volume":"17","author":"EJ Bastyr","year":"2015","unstructured":"Bastyr, E. J. et al. Performance of an electronic diary system for intensive insulin management in global diabetes clinical trials. Diab. Technol. Ther. 17, 571\u2013579 (2015).","journal-title":"Diab. Technol. Ther."}],"updated-by":[{"DOI":"10.1038\/s41746-026-02396-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000}}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02165-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:39:36Z","timestamp":1769495976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02165-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02165-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41746-026-02396-w","URL":"https:\/\/doi.org\/10.1038\/s41746-026-02396-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FDM is a full-time employee of uMotif. JT and RNC are full-time employees of Eli Lilly and Company. JP was a full-time employee of Suvoda. JB is full-time employee and shareholder of UCB. EF is a full-time employee and stockholder of AstraZeneca. JLA is a full-time employee of AbbVie and owns stock\/stock options. KD is a full-time employee of Clario.POD is a full-time employee of Medidata Solutions. SG was a full-time employee of Parexel International and has no competing interests to declare. SDK is a full-time employee and stockholder of GSK. DO is a full-time employee of Otsuka. RW is a full-time employee of Novartis and stockholder of Novartis and Pfizer. MB was a full-time employee of Signant Health. NS is a full-time employee of Parexel International and has no competing interests to declare. LH is a full-time employee of IQVIA. AF is a full-time employee of Medrio. LR is a full-time employee of AbbVie. SE and SK are full-time employees of Critical Path Institute and have no competing interests to declare. OI, JJ, MF and MC are full-time employees of the US Food and Drug Administration and have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"745"}}